Soley Therapeutics reports data on new CKAP2 modulator STX-6398

Cytoskeleton-associated protein 2 (CKAP2) is the most potent microtubule growth factor identified so far and is considered an undruggable protein, often associated with malignant progression in cancer by targeting the FAK-ERK2 signaling pathway. Using its proprietary platform, Soley Therapeutics Inc. has discovered a small molecule that modulates CKAP2 – STX-6398.
2026-05-11 13:00:00